norelgestromin + ethinyl estradiol; triphasil.
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Contraception
Conditions
Contraception, Female Contraception
Trial Timeline
Jan 1, 1997 → Mar 1, 1999
NCT ID
NCT00236795About norelgestromin + ethinyl estradiol; triphasil.
norelgestromin + ethinyl estradiol; triphasil. is a phase 3 stage product being developed by Johnson & Johnson for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00236795. Target conditions include Contraception, Female Contraception.
What happened to similar drugs?
15 of 20 similar drugs in Contraception were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00236795 | Phase 3 | Completed |
Competing Products
20 competing products in Contraception